SN. heads into the week after its first significant corporate catalyst of 2026 — a Q1 trading update paired with a $500m buyback announcement — with short sellers modestly trimming positions even as the stock remains down 4% over the past month.
The most notable shift this week is in short interest. Bears have been quietly building since early April, with SI climbing from 3.2% of free float at the start of that month to 4.6% by late April — a 43% increase in just four weeks. The latest reading has pulled back to 4.3% of free float, suggesting some covering followed the Q1 update. That level is still meaningfully above where the stock was entering April, and it's worth watching whether the retreat holds. The borrowing market offers little urgency for either side: borrow costs run at just 0.56% annualised, and availability is extraordinarily loose at nearly 2,962% of short interest. There is no squeeze pressure here, and new shorts can be put on cheaply.
The Q1 update delivered an in-line performance with full-year guidance reiterated, but the headline masked a softer detail. US knee implant sales disappointed, even as other divisions held up. The company still sees FY2026 revenue around $6.5bn — essentially in line with the $6.56bn consensus — but the missed estimate (however narrow) reinforced existing concerns about the pace of the orthopaedics recovery. The $500m buyback was the session's positive surprise, contributing to a 1% bounce on the day. With the next scheduled event on 9 June, the Q1 print now frames the debate: execution versus the tariff headwind that several health tech CEOs flagged publicly this week.
The Street remains constructive by a wide margin. The analyst consensus mean price target of £19.21 implies roughly 66% upside from the current price of £11.59 — a gap that reflects either deep value or lingering scepticism about delivery timelines, depending on your starting point. The ORTEX short score of 50.4 is broadly neutral, having edged down from a recent peak near 51.2, consistent with the modest short-covering seen after the update. Factor rankings offer a mixed read: the dividend score ranks in the 74th percentile, pointing to income support, while EPS surprise sits in only the 25th percentile — short sellers have history on their side when it comes to Smith & Nephew undershooting on earnings.
BlackRock remains the standout institutional holder, sitting at 9.3% of shares with a notable net addition of 16.2 million shares in the most recently reported period. That is a meaningful conviction add from the world's largest asset manager. Massachusetts Financial Services and Brandes Investment Partners both added materially too, while Norges Bank trimmed just over a million shares. The net direction of institutional flow is constructive, though the concentration at the top of the register means BlackRock's next disclosed move will be closely watched.
The earnings history offers a sobering reference point: the March 2026 full-year results saw the stock give up 0.8% on the day and 8.7% over the subsequent five sessions — a pattern of relief-rally relief followed by drift lower that the market will remember heading into the June interim. With availability extremely loose, borrow costs negligible, and the short base still elevated relative to early April, the June print rather than any near-term catalyst is where the next positioning decision gets made.
See the live data behind this article on ORTEX.
Open SN. on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
